Yinghong Wang, MD, PhD, from The University of Texas MD Anderson Cancer Center, Houston, TX, discusses their fecal transplant trials for treating refractory colitis caused by immune checkpoint inhibitors. The first trial, initiated six years ago, achieved an 85% success rate in patients who failed standard treatments. The newer frontline fecal transplant trial (NCT04038619), started a year and a half ago, showed a promising 75% success rate among eight patients. These trials offer hope for more effective and minimally immunosuppressive treatments for immune checkpoint inhibitor-induced colitis. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
